Attached files

file filename
EXCEL - IDEA: XBRL DOCUMENT - Q Therapeutics, Inc.Financial_Report.xls
XML - IDEA: XBRL DOCUMENT - Q Therapeutics, Inc.R2.htm
XML - IDEA: XBRL DOCUMENT - Q Therapeutics, Inc.R5.htm
XML - IDEA: XBRL DOCUMENT - Q Therapeutics, Inc.R6.htm
XML - IDEA: XBRL DOCUMENT - Q Therapeutics, Inc.R8.htm
XML - IDEA: XBRL DOCUMENT - Q Therapeutics, Inc.R4.htm
XML - IDEA: XBRL DOCUMENT - Q Therapeutics, Inc.R3.htm
XML - IDEA: XBRL DOCUMENT - Q Therapeutics, Inc.R1.htm
XML - IDEA: XBRL DOCUMENT - Q Therapeutics, Inc.R9.htm
XML - IDEA: XBRL DOCUMENT - Q Therapeutics, Inc.R10.htm
XML - IDEA: XBRL DOCUMENT - Q Therapeutics, Inc.R17.htm
XML - IDEA: XBRL DOCUMENT - Q Therapeutics, Inc.R12.htm
XML - IDEA: XBRL DOCUMENT - Q Therapeutics, Inc.R18.htm
XML - IDEA: XBRL DOCUMENT - Q Therapeutics, Inc.R24.htm
XML - IDEA: XBRL DOCUMENT - Q Therapeutics, Inc.R13.htm
XML - IDEA: XBRL DOCUMENT - Q Therapeutics, Inc.R22.htm
XML - IDEA: XBRL DOCUMENT - Q Therapeutics, Inc.R19.htm
XML - IDEA: XBRL DOCUMENT - Q Therapeutics, Inc.R21.htm
XML - IDEA: XBRL DOCUMENT - Q Therapeutics, Inc.R20.htm
XML - IDEA: XBRL DOCUMENT - Q Therapeutics, Inc.R16.htm
XML - IDEA: XBRL DOCUMENT - Q Therapeutics, Inc.R23.htm
XML - IDEA: XBRL DOCUMENT - Q Therapeutics, Inc.R14.htm
XML - IDEA: XBRL DOCUMENT - Q Therapeutics, Inc.R25.htm
XML - IDEA: XBRL DOCUMENT - Q Therapeutics, Inc.R11.htm
EX-3.1 - Q Therapeutics, Inc.ex3-1.htm
EX-3.2 - Q Therapeutics, Inc.ex3-2.htm
EX-32.1 - Q Therapeutics, Inc.ex32-1.htm
EX-32.2 - Q Therapeutics, Inc.ex32-2.htm
EX-14.1 - Q Therapeutics, Inc.ex14-1.htm
EX-31.2 - Q Therapeutics, Inc.ex31-2.htm
EX-31.1 - Q Therapeutics, Inc.ex31-1.htm
10-Q - Q Therapeutics, Inc.form10q.htm
XML - IDEA: XBRL DOCUMENT - Q Therapeutics, Inc.R7.htm
v2.4.0.6
Stock Options and Warrants (Tables)
9 Months Ended
Sep. 30, 2012
Stock Options And Warrants  
Outstanding Common Stock Options

The following sets forth the outstanding common stock options and related activity for the nine months ended September 30, 2012:

 

          Weighted  
          Average  
    Number of     Exercise  
    Options     Price Per Share  
             
Outstanding as of December 31, 2011     3,156,948     $ 0.14  
Granted     850,000       1.00  
Exercised     -       -  
Forfeited     -       -  
                 
Outstanding as of March 31, 2012     4,006,948       0.32  
Granted     -       -  
Exercised     -       -  
Forfeited     (149,057 )     0.08  
                 
Outstanding as of June 30, 2012     3,857,891       0.33  
Granted     40,000       1.00  
Exercised     (32,451 )     0.06  
Forfeited     -       -  
                 
Outstanding as of September 30, 2012     3,865,440       0.34  

Fair Value of Stock-Based Compensation Award Granted, Assumptions

The fair value of each stock-based compensation award granted during the nine months ended September 30, 2012, was estimated on the date of grant using the Black-Scholes option-pricing model with the following assumptions:

 

Risk-free interest rate 1.40%  
Expected stock price volatility 63.73%  
Expected dividend yield 0%  
Expected life of options 5.6 years  

Stock Options Outstanding

 

The following summarizes information about stock options outstanding as of September 30, 2012:

 

 

Exercise
Price
    Number of Options Outstanding     Weighted
Average
Remaining
Contractual
Life (Years)
    Weighted
Average
Exercise
Price
    Number
of Options
Exercisable
    Weighted Average Exercise
Price
 
                                 
  $ 0.06 – 0.08       902,600       6.66     $ 0.08       902,600     $ 0.08  
  0.15 – 0.19        2,072,840       6.53       0.17       1,988,709       0.17  
  1.00       890,000       9.34       1.00       187,500       1.00  
                                             
          3,865,440       7.21       0.34       3,078,809       0.19  

Summary of Stock Warrants Exercisable

      Warrants
In connection with certain stock offerings and debt issuances, the Company has issued warrants to purchase common stock. The following summarizes information about stock warrants as of September 30, 2012, all of which are exercisable:

 

Warrants   Year of
Expiration
    Number of Shares     Exercise Price  
                   
Common stock warrants issued for previously issued Series A2 warrants     2015       132,797     $ 0.046  
                         
Common stock warrants issued for previously issued Series B warrants     2015       823,347       1.035  
                         
Common stock warrants issued for previously issued Series B warrants     2017       192,242       0.532  
                         
Warrants issued in conjunction with bridge notes (August 31, 2011)     2018       1,816,644       1.00  
                         
Warrants issued in conjunction with bridge notes (August 31, 2011)     2018       916,644       2.00  
                         
Warrants issued in conjunction with private placement (October 13 and December 30, 2011)     2018       3,828,047       1.00  
                         
Warrants issued in conjunction with private placement (October 13 and December 30, 2011)     2018       3,828,047       2.00  
                         
Warrants issued for fees in conjunction with reverse merger (October 13 and December 30, 2011)     2018       22,750       1.20  
                         
Warrants issued in conjunction with private placement (February 2 and March 30, 2012)     2019       190,000       1.00  
                         
Warrants issued in conjunction with private placement (February 2 and March 30, 2012)     2019       190,000       2.00  
                         
Warrants issued for fees in conjunction with private placement (February 2 and March 30, 2012)     2019       19,000       1.20  
                         
Warrants issued in conjunction with asset purchase agreement (April 9, 2012)     2019       10,000       1.00  
                         
Warrants issued in conjunction with asset purchase agreement (April 9, 2012)     2019       10,000       2.00  
              11,979,518